Target intelligence / Profile preview

MARK2 pseudogene 17 (MARK2P17)

Target
MARK2P17
Molecular classification
Pseudogene, Non-coding RNA (may be processed/duplicated)
01

Overview

MARK2 pseudogene 17 (MARK2P17) is a human pseudogene, characterized as a non-functional genomic sequence homologous to the protein-coding MARK2 gene (Microtubule Affinity Regulating Kinase 2). Pseudogenes typically do not encode functional proteins; instead, some may be transcribed as non-coding RNAs and act through regulatory mechanisms such as miRNA sponging, antisense transcript formation, or competing endogenous RNA (ceRNA) networks. MARK2P17 itself has not been identified as a therapeutic target, nor are there any drugs or disease roles directly associated with it. Its designation as a pseudogene means it is generally not the focus of drug discovery or biomarker development, and no protein product or classic receptor/enzyme function exists for MARK2P17. If you are interested in the canonical biological target, refer to Microtubule Affinity Regulating Kinase 2 (MARK2), a serine/threonine kinase involved in cell polarity and microtubule dynamics.

Other names
MARK2P17100421499 (NCBI Gene)ENSG00000244065 (Ensembl)
02

Mechanism of action

Not applicable (no direct protein product or established role)

03

Biological functions

None directly attributable; possible regulatory functions via RNA mechanisms (such as miRNA sponging, antisense regulation of parent gene, ceRNA roles which may influence expression of parent MARK2 or related genes in some contexts)
04

Disease associations

None established; generally, some pseudogenes have been implicated in regulation of diseases when acting as ceRNAs or regulatory RNAs, but no evidence links MARK2P17 with specific diseases

Beyond the preview

Go deeper on MARK2 pseudogene 17 (MARK2P17).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MARK2 pseudogene 17 (MARK2P17).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call